

Evaluation of antimicrobial efficacy of extracts from the bark of a semi arid plant *Albizia lebbbeck* (L.) Benth

Priyanka Jaiswal* and Padma Kumar

Laboratory of plant tissue culture and secondary metabolites, Department of Botany, University of Rajasthan

Received 21 January 2016; Revised 03 September 2016

In the present study, use of ethnomedicinal plant/ plant parts for the treatment of disease with little or no side effect is investigated against the pathogens related to infectious diseases. Bark of *Albizia lebbbeck* (L.) Benth was collected and air dried and soxhlet extracted by using standard methods for flavonoid, alkaloid, steroid and different solvents. These extracts were then tested for antimicrobial activity using disc diffusion method. Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and total activity (TA) were also calculated. Statistical analysis like mean value and standard deviation were calculated for the test bacteria and fungi. Data was analyzed by one-way analysis of variance and *P* values were considered significant at $P > 0.005$. Among the seven extracts, methanol extract exhibited highest inhibition zone (20 mm) against *R. planticola*. *P. aeruginosa*, *S. aureus*, and *R. planticola* were observed to be more susceptible pathogens in the investigation followed by *B. subtilis*, *E. aerogenes*, and *E. coli*. Bound flavonoid and methanolic extracts of the bark of *A. lebbbeck* were found to be most bioactive. The range of MIC and MBC of extracts recorded was 0.625-0.078 mg/mL and 0.312- 0.039 mg/mL, respectively. The lowest MIC value 0.078 mg/mL was recorded against *R. planticola*, indicating significant antimicrobial potential of test extracts. High values of TA were observed against *R. planticola*, followed by *S. aureus*. Results of the present study revealed that the bark extracts of *A. lebbbeck* showed great antimicrobial potential against the tested microorganisms and may be exploited for future antimicrobial drugs.

Keywords: Alkaloid, Antimicrobial, Flavonoid, Minimum bactericidal concentration, Minimum inhibitory concentration, Steroid, Total activity.

IPC code; Int. cl. (2015.01)– A61K 36/00

Introduction

Our country has diverse climate, which supports growth of varieties of plants. Plants are used as medicine from ancient time and even now these herbal medicines are in continuous demand. Plants have become an essential and integral part in complementary and alternative medicine. Plants have the ability to form secondary metabolites like proteins, flavonoids, alkaloids, steroids, and phenolic substances, which are in turn used to restore health and heal many diseases¹.

Albizia lebbbeck (L.) Benth known as *Shirisha* in *Ayurveda* is an important medicinal plant belonging to the family Fabaceae and a member of subfamily Mimosaceae. The bark is dark brown to greenish black, rough, with longitudinal and transverse fissures on the outer surface; inner surface whitish with fine longitudinal stations. It is a tree of great importance in India and has traditionally been used as a cure for

many harmful diseases. *A. lebbbeck* bark has an acrid taste and is used for bronchitis, leprosy, paralysis, and helminth infections and is reported to have antidiarrhoeal activity². Barks are mainly used in dental infections³. The bark of *A. lebbbeck* is also used in the treatment of piles⁴. It also possesses anti-spermatogenic and anti-inflammatory activity^{5,6}.

In recent years, multiple drug resistance has been developed in pathogens of human and plant due to indiscriminate use of synthetic drugs especially in the developing countries⁷. Thus, a diverse arsenal of new antibacterial agents is urgently needed to combat the diminishing efficacy of existing antibiotics⁸. It is reported that *A. lebbbeck* contains saponins, macrocyclic alkaloids, anthraquinone glycosides, tannins, and flavonols⁹. A novel phenolic glycoside, albizinin and four known flavanols, (-) epicatechin, procyanidin B-2, procyanidin B-5, and procyanidin C-1, also had been isolated from the acetone extract of the bark¹⁰. Phytochemical and therapeutic efficacy studies of *A. lebbbeck* have been reported¹¹. The present investigation was undertaken to find out

*Correspondent author
Email: priyankajaiswal.micro@gmail.com

the antibacterial potential of flavonoids, alkaloids, steroids, and extracts with different polarity of the bark of *A. lebbeck* against some Gram-positive and Gram-negative bacteria.

Escherichia coli is a frequent cause of life threatening bloodstream infections¹² and other common infections, such as urinary tract infections. Antibiotic resistance rates in *E. coli* are rapidly rising, especially with regard to fluoroquinolones, and third- and fourth-generation cephalosporins^{13,14}. *Raoultella planticola* is a Gram negative, aerobic, nonmotile bacilli primarily considered to be an environmental bacteria. It rarely causes human infections¹⁵. However, an increasing number of cases of *R. planticola* infection, including bacteraemia, soft tissue infection pancreatitis and urinary tract infection have recently been reported¹⁶. *Pseudomonas aeruginosa* is one of the leading nosocomial pathogens worldwide¹⁷. It exhibits antibiotic resistance, and demonstrates practically all known enzymic and mutational mechanisms of bacterial resistance¹⁸. *Enterobacter aerogenes* is a common agent of hospital-acquired infection. It exhibits a remarkable adaptive capability and easily acquires resistance to β -lactam antibiotics during therapy¹⁹. The existence of a prevalent resistant clone of *E. aerogenes* has been reported²⁰. In addition, antibiotic resistance of *E. aerogenes* is associated with a high crude fatality rate in infected patients²¹. *Agrobacterium tumefaciens* is a tumor producing pathogenic bacteria and is a serious pathogen of walnuts, grape vines, and stone fruit. Pathogenic potential of *Bacillus subtilis* is generally described as low or absent²². In the literature, only a few cases of infections due to *B. subtilis* are reported²³ and only one retrospective study describes the isolation of antibiotic-resistant strains of *B. subtilis*²⁴. *Staphylococcus aureus* is the most common hospital acquired pathogen and causes staph infections which is responsible for various diseases including mild skin infections (like folliculitis), invasive diseases (like wound infections and bacteraemia), and toxin mediated diseases (like food poisoning, toxic shock syndrome and scalded skin syndrome). In infants, its infection can cause a severe disease called staphylococcal scalded skin syndrome²⁵. Bacteraemia due to *S. aureus* has been reported to be associated with mortality rates of 15–60 %^{26,27}. Resistance to methicillin among *S. aureus* isolates is a growing problem: the prevalence of nosocomial infections in patients increased from 12.5 % in 1999 to 20.8 % in 2004²⁸.

Materials and Methods

Collection of plant material

Bark of *A. lebbeck*, was collected from Jaipur located in the eastern region of Rajasthan in June 2014. Plant was identified by a senior taxonomist, Dr. Sudhakar Mishra of the Department of Botany, University of Rajasthan and a voucher specimen (RUBL211460) was deposited in the Herbarium of the same Department of Botany.

Selected test pathogens

Seven pathogens, namely *Escherichia coli* (MTCC no. 46), *Pseudomonas aeruginosa* (MTCC no. 1934), *Raoultella planticola* (MTCC 2272), *Enterobacter aerogenes* (MTCC no. 2822), *Bacillus subtilis* (MTCC no. 121), *Agrobacterium tumefaciens* (MTCC no. 431), and *Staphylococcus aureus* (MTCC no. 87) were selected for the present study and were procured from CSIR-IMTECH, Chandigarh, India. The bacterial strains were grown and maintained on Mueller-Hinton agar medium.

Preparation of extracts

Flavonoid extraction²⁹

Bark of *A. lebbeck* was collected; shade dried, finely powdered and extracted using the method of Subramanian & Nagarjan. Finely powdered sample (100 g) was soxhlet extracted with 80 % hot methanol (500 mL) on a water bath for 24 h and filtered. Using separating funnel the filtrate obtained was re-extracted successively with petroleum ether (fraction I), ethyl ether (fraction II), and ethyl acetate (fraction III). Fraction of petroleum ether was discarded due to being rich in fatty substances, where as fractions of ethyl ether and ethyl acetate were further analyzed for free and bound flavonoids, respectively. Using 7 % H₂SO₄, ethyl acetate fraction of the sample was refluxed for the hydrolysis for 2 h (for removal of bounded sugars) and again filtrate was extracted in separating funnel with ethyl acetate. Ethyl acetate extract thus obtained was washed with distilled water to neutrality. Ethyl ether (free flavonoids) and ethyl acetate fractions (bound flavonoids) were dried in vacuum and weighed. The extracts were stored at 4 °C and were re-suspended in acetone to get 10 mg/mL concentration for antimicrobial assay.

Alkaloids extraction³⁰

Finely powered sample (100 g) was extracted in 20 mL methanol after shaking for 15 min. After

filtration, filtrate was dried in vacuum and then the residual mass was treated with 1 % H_2SO_4 (5 mL twice). Extraction was then done in 10 mL chloroform ($CHCl_3$) by using separating funnel. Organic layer of chloroform was rejected and aqueous layer was basified with 30 % NH_4OH (PH=9-10). Once again, extraction was done in 10 mL chloroform and the organic layer of chloroform (lower layer) was collected in a flask and the above steps were repeated with fresh chloroform. Extract was then dried in vacuum for further use.

Steroid extraction³¹

Finely powdered sample (100 g) was extracted in petroleum ether for 2-4 h. After filtration, residual mass was treated with 15 % ethanolic HCl for 4 h. Extraction was then done in ethyl acetate followed by washing in distilled water to neutralize the extract. The neutral extract was then passed over sodium sulphate to remove moisture contents and was dried in vacuum. Chloroform was used for reconstitution of extract, filtered, and dried for further use.

Extraction in different polar solvents

Powdered bark (20 g) was taken in each flask and water, methanol, and petroleum ether were used as the solvent. Dried material and solvents were taken in 1:10 ratio. Those were kept at soxhlet unit for 24 h. The obtained extracts were filtered by using Whatman No. 1 filter paper and the filtrate was subjected to evaporation to obtain dried extract. The percentage yield of each dried plant extract was calculated. The residual extracts were stored in a refrigerator at 4 °C in small and sterile glass bottles.

Antimicrobial susceptibility testing

Disc diffusion assay³² was performed for screening. Mueller- Hinton agar base plates were seeded with the bacterial inoculums of size 1×10^8 CFU/mL. Sterile filter paper discs of Whatman no.1 (6 mm diam.) were impregnated with 100 μ L of each of the extract (concentration- 10 mg/mL) to give a final concentration of 1 mg/disc. Discs were left to dry in vacuum, so as to remove residual solvent, which might interfere with the determination. Discs with extract were then placed on the corresponding seeded agar plates. Each extract was tested in triplicate along with streptomycin (1 mg/disc) as a standard for bacteria. The plates were kept at 4 °C for diffusion of extract, thereafter were incubated at 37 °C for 24 h. Activity index for each extract was calculated by the following formula:

Activity index = $\frac{IZ \text{ produced by extract}}{IZ \text{ produced by standard}}$
Where, IZ = inhibition zone.

Determination of MIC and MBC

Minimum inhibitory concentration (MIC) was determined for each plant extract showing antimicrobial activity against test pathogens. Broth micro dilution method³³ was followed for determination of MIC values. Plant extracts were resuspended in acetone (which has no activity against test microorganisms) to make 10 mg/mL final concentration. Two fold serially diluted extracts were added to broth media of 96-wells of micro titer plates. Thereafter, 100 μ L inoculum (1×10^8 CFU/mL) was added to each well. Bacterial suspensions were used as negative control, while broth containing standard drug was used as positive control. Micro titer plates were then incubated at 37 °C for 24 h. Each extract was assayed in duplicate and each time two sets of micro plates were prepared, one was kept for incubation while another was kept at 4 °C for comparing the turbidity in the wells of micro plate. The MIC values were taken as the lowest concentration of the extracts in the well of a micro titer plate that showed no turbidity after incubation. The turbidity of the wells in the micro titer plate was interpreted as visible growth of microorganisms. The minimum bactericidal concentration (MBC) was determined by sub culturing 50 μ L from each well showing no apparent growth. Least concentration of extract showing no visible growth on sub culturing was taken as MBC.

Total activity determination³⁴

Total activity (TA) is the volume at which the test extract can be diluted without losing the ability to kill microorganisms. It is calculated by dividing the amount of extract from 1 g of plant material by the MIC of the same extract or compound isolated and is expressed in mL/g.

Results

The result of the assessment of antimicrobial potency of flavonoids (bound and free), alkaloid, steroids, and extract obtained with different solvents (water, methanol, and petroleum ether) showed significant activity against most of the tested pathogens (Table 1-3). In the present investigation, results revealed that out of total seven extracts tested against seven different pathogens, alkaloid extract of bark remained inactive against all pathogens.

Among the seven extracts, methanol extract exhibited highest inhibition zone (20 mm) against *R. planticola*. *P. aeruginosa*, *S. aureus*, and *R. planticola* were observed to be more susceptible pathogens in the investigation followed by *B. subtilis*, *E. aerogenes*

and *E. coli*. Significant activity index was observed for bound flavonoid and petroleum ether extract against *P. aeruginosa* and *B. subtilis*, respectively. Bound flavonoid and methanolic extracts of the bark of *A. lebbbeck* were found to be the most bioactive

Table 1—Antimicrobial activity of extracts of *Albizia lebbbeck* against some pathogenic bacteria

Extract	Microorganisms													
	<i>E. coli</i>		<i>P. aeruginosa</i>		<i>R. planticola</i>		<i>E. aerogenes</i>		<i>B. subtilis</i>		<i>A. tumefaciens</i>		<i>S. aureus</i>	
	IZ	AI	IZ	AI	IZ	AI	IZ	AI	IZ	AI	IZ	AI	IZ	AI
F1	12	16	1.23±0.022			11	0.	12						
F2	-	8	0.615±0.068			9	0.6±0.055						9	0.333±0.025
A	-	-	-											
S	-	10	0.769±0.062	10	0.588±0.059								10	0.37±0.014
W	-	12	0.705±0.056		-									
M	-	12	0.923±0.023	20	176±0.016	13	0.86±0.445	15	1.153±0.025				16	0.592±0.088
P	-	15	1.153±0.052	12	0.705±0.032			16	1.23±0.016				12	0.444±0.033

values are Mean±SEM, IZ- Inhibition zone in mm (including 6 mm diam. of disc); F1- Bound flavonoids; F2- Free flavonoids; A- Alkaloids; S- Steroids; W- Water extract; M- Methanol extract; P- Petroleum ether extract; (-)- no activity.

Table 2—MIC and MBC of active extracts of *Albizia lebbbeck* against different pathogens

Microorganisms	Extracts	F1	F2	A	S	W	M	P
<i>E. coli</i>	MIC	0.312	-	-	-	-	-	-
	MBC	0.156	-	-	-	-	-	-
<i>P. aeruginosa</i>	MIC	0.156	0.625	-	0.625	-	0.312	0.312
	MBC	0.078	0.312	-	0.312	-	0.156	0.156
<i>R. planticola</i>	MIC	-	-	-	0.625	0.312	0.078	0.312
	MBC	-	-	-	0.312	0.156	0.039	0.156
<i>E. aerogenes</i>	MIC	0.312	0.625	-	-	-	0.312	-
	MBC	0.156	0.312	-	-	-	0.156	-
<i>B. subtilis</i>	MIC	0.312	-	-	-	-	0.312	0.156
	MBC	0.312	-	-	-	-	0.156	0.078
<i>A. tumefaciens</i>	MIC	0.312	-	-	-	-	-	-
	MBC	0.156	-	-	-	-	-	-
<i>S. aureus</i>	MIC	-	0.625	-	0.625	-	0.156	0.312
	MBC	-	0.312	-	0.312	-	0.078	0.156

F1- Bound flavonoids; F2- Free flavonoids; A- Alkaloids; S- Steroids; W- Water extract; M- Methanol extract; P- Petroleum ether extract; MIC- Minimum inhibitory concentration in mg/mL; MBC- Minimum bactericidal concentration in mg/mL; (-)- no activity

Table 3—Quantity and total activity of extracts of *Albizia lebbbeck*

Extracts	Quantity of extract mg/g dwt	Total activity (mg/mL)						
		<i>E. coli</i>	<i>P. aeruginosa</i>	<i>R. planticola</i>	<i>E. aerogenes</i>	<i>B. subtilis</i>	<i>A. tumefaciens</i>	<i>S. aureus</i>
F1	7.5	24.03	48.07	-	24.03	24.03	24.03	-
F2	4.0	-	6.4	-	6.4	-	-	6.4
A	65.0	-	-	-	-	-	-	-
S	9.0	-	14.4	14.4	-	-	-	14.4
W	11.0	-	-	35.25	-	-	-	-
M	192.0	-	615.4	2462	615.4	615.4	-	1231
P	1.0	-	3.205	3.205	-	6.41	-	3.205

F- Bound flavonoids; F2- Free flavonoids; A- Alkaloids; S- Steroids; W- Water extract; M- Methanol extract; P- Petroleum ether extract; TA- Total activity (extract per g dried plant part/MIC of extract)

metabolite, as activity was observed against most of the tested pathogens. MIC and MBC values (Table 2) were evaluated for plant extracts, which had shown activity in diffusion assay. The range of MIC and MBC of extracts recorded was 0.625-0.078 mg/mL and 0.312- 0.039 mg/mL, respectively. In the present investigation, lowest MIC value of 0.078 mg/mL was recorded against *R. planticola*, indicating a significant antimicrobial potential of test extracts. The quantity of extracts per gram of plant material and TA calculated was recorded (Table 3). High values of TA were observed against *R. planticola* followed by *S. aureus*.

Discussion

In the recent years, infections have increased to a great extent and the antibiotics resistance has become an ever-increasing therapeutic problem³⁵. In India, medicinal plants are widely used directly as folk remedies or indirectly in the pharmaceutical preparations. They are effective in the treatment of infectious diseases while simultaneously mitigating many of the side effects that are often associated with synthetic medicines³⁶. Hence, continuous investigations related to medicinal plants are required for the discovery of new drugs. The present study was an effort to investigate the medicinal properties of *A. lebeck*, which has not yet been carried out in the earlier studies. In an earlier study, it was reported that the hydroalcoholic extract of *A. lebeck* exhibited antibacterial activity³⁷, and the preliminary phytochemical screening of the ethanolic extract of the bark showed the presence of alkaloids, glycosides, flavanoids, saponins, tannins, carbohydrates and reducing sugar, while the ethanolic extract of the pods showed the presence of proteins, glycosides, flavanoids, saponins, tannins, carbohydrates and reducing sugar, which suggests that the plant may possess various pharmacological activities³⁸. The methanol and the chloroform extracts of the seeds of *A. lebeck* have been reported to inhibit the growth of pathogens. *B. subtilis* and *Aspergillus fumigatus* have been reported to be highly sensitive towards chloroform extract of seeds and methanol extract of seeds showed good activity against *B. subtilis* and *Candida albicans*. Chloroform extract has been reported to be more effective against *B. subtilis* than methanol extract residue³⁹. A study by Srinivasan *et al.*⁴⁰ showed that the aqueous extract possesses antibacterial activity against *E. coli* and *Salmonella* spp. Although, the plant has been studied previously

for its antimicrobial activity, but so far, it has not been investigated for bark flavonoids, alkaloids, steroids and extracts obtained in different polar and non-polar solvents. Mostly, the crude extracts of leaf, stem, flower, and root without MIC, MBC, and TA determination have been screened. Such studies could only indicate their antimicrobial potential, but are not helpful in establishing them as an antibiotic, hence can't replace the existing antibiotics. In the present investigation, IZ, AI, MIC, MBC, and TA have been evaluated for each extract. Extracts recorded for low MIC values indicate strong bioefficacy of the plant. The findings of the present investigation offer a scientific evidence to support the ethnomedicinal use of the plants as an alternative medicine.

Conclusion

A. lebeck, a traditional medicinal plant of India, is a rich source of bioactive compound. As of now, little work has been done on the biological activity and hence, extensive investigation is needed to exploit the bioactive compounds for medicinal purpose. The results of the above study revealed that the extracts of *A. lebeck* exhibits antibacterial activity, which might be helpful in preventing the progress of various diseases and can be used in the alternative system of medicine.

Acknowledgement

The authors are thankful to the Head, Department of Botany, University of Rajasthan, Jaipur and to UGC for financial assistance (No. F-41-4/NET/RES/JRF-1264/2388 dt. 22-05-2013).

References

- 1 Chaudhary M, Sharma A K, Kumar R, Chauhan B, Kaushik K and Agarwal V, Comparative immunomodulator activity of leaves and bark of *Albizia lebeck*, *Int J Res Develop Pharm Life Sci*, 2012, **1**(1), 25-27.
- 2 Uma B, Prabhakar K, Rajendran S and Lakshmi S Y, Antimicrobial Activity of *Albizia Lebeck* Benth against Infectious Diarrhoea, *Internet J Microbiol*, 2008, **7**(1), 1-5.
- 3 Besra S E, Gomes A, C haudhary L, Vedasiromoni J R and Ganguly D K, Antidiarrhoeal activity of seed extract of *Albizia lebeck* studied on conventional rodent models of diarrhoea, *Phytotherapy Res*, 2002, **16**(6), 529-30.
- 4 Zia-Ul-Haq M, Ahmad S, Qayum M and Ercisli S, Compositional studies and antioxidant potential of *Albizia lebeck* (L.) Benth. pods and seeds, *Turkish J Biol*, 2013, **37**, 25-32.
- 5 Gupta R S, Kachhawa J B and Chaudhary R, Antispermatic, antiandrogenic activities of *Albizia lebeck* (L.) Benth bark extract in male albino rats, *Phytomed*, 2006, **13**(4), 277-83.

- 6 Pratibha N, Saxena V S, Amit A, D'Souza P, Bagchi M and Bagchi D, Anti-inflammatory activities of Aller-7, a novel polyherbal formulation for allergic rhinitis, *Int J Tissue React*, 2004, **26**(1-2), 43-51.
- 7 Hart C A and Karriuri S, Antimicrobial resistance in developing countries, *Bio Med J*, 1998, **317**, 421-452.
- 8 Chopra I, Hodgson J, Metcalf B and Poste G, The search for antibacterial agents effective against bacteria resistance to multiple antibiotics, *Antimicrob Agent Chemother*, 1997, **41**, 497-503.
- 9 Rahul C, Pankaj P, Sharma K S and Jhajharia K M, Phytochemical screening and antimicrobial activity of *Albizia lebeck*, *J Chem Pharm Res*, 2010, **2**(5), 476-486.
- 10 Varshney I P, Vyas P, Shrivastav H C and Singh P P, Study of *Albizia lebeck* Benth wood saponin, Lebbekinin- E, *Natl Acad Sci Lett*, 1979, **2**, 135-136.
- 11 Sharma G K and Dubey N, Review of Shirish (*Albizia lebeck*) therapeutic properties, *Int J Ayur Herb Med*, 2015, **5**(1), 1683-1688.
- 12 Kennedy K J, Roberts J L and Collignon P J, *Escherichia coli* bacteraemia in Canberra: Incidence and clinical features, *Med J Aust*, 2008, **188**, 209-13.
- 13 Laupland K B, Church D L, Vidakovich J, Mucenski M and Pitout J D, Community-onset extended-spectrum b-lactamase (ESBL)-producing *Escherichia coli*: Importance of international travel, *J Infect*, 2008, **57**, 441-8.
- 14 Mesa R J, Blanc V and Blanch A R, Extended spectrum b-lactamase-producing Enterobacteriaceae in different environments (humans, food, animal farms, and sewage), *J Antimicrob Chemother*, 2006, **58**, 211-5.
- 15 Drancourt M, Bollet C, Carta A and Rousselier P, Phylogenetic analyses of *Klebsiella* species delineate *Klebsiella* and *Raoultella* gen. nov., with description of *Raoultella ornithinolytica* comb. nov., *Raoultella terrigena* comb. nov. and *Raoultella planticola* comb. nov. *Int J Syst Evol Microbiol*, 2001, **51**, 925-932.
- 16 Chen D Q, Song J L, Tang H X, Yang L, Wu A W and Lin Y P, Extensively drug-resistant *Raoultella planticola* carrying multiple resistance genes including blaNDM-1. *JMM Case Reports*, 2014, **1**, 1-3
- 17 Blanc D S, Petignat C, Janin B, Bille J and Francioli P, Frequency and molecular diversity of *Pseudomonas aeruginosa* upon admission and during hospitalization: A prospective epidemiologic study, *Clin Microbiol Infect*, 1998, **4**, 242-247.
- 18 Pechere J C and Kohler T, Patterns and modes of b-lactam resistance in *Pseudomonas aeruginosa*, *Clin Microbiol Infect* 1999, **5** (1), S15-S18.
- 19 Arpin, C, Coze C, Rogues A M, Gachie J P, Bebear C and Quentin C, Epidemiological study of an outbreak due to multidrug-resistant *Enterobacter aerogenes* in medical intensive care units, *J Clin Microbiol*, 1996, **34**, 2163-2169.
- 20 Bosi C, Davin-Regli A, Bornet C, Malle'a M, Page's J M and Bollet C, Most *Enterobacter aerogenes* strains in France belong to a prevalent clone, *J Clin Microbiol*, 1999, **37**, 2165-2169.
- 21 Gayet S, Chollet R, Molle G, Page's J M and Chevalier J, Modification of outer membrane protein profile and evidence suggesting an active drug pump in *Enterobacter aerogenes* clinical strains, *Antimicrob, Agents Chemother*, 2003, **47**, 1555-1559.
- 22 de Boer A S, and Diderichsen B, On the safety of *Bacillus subtilis* and *B. amyloliquefaciens*: A review, *Appl Microbiol Biotechnol*, 1991, **36**, 1-4.
- 23 Kiss T, Gratwohl A, Frei R, Osterwalder B, Tichelli A and Speck B, *Bacillus subtilis* infections. *Schweiz Rundsch Med Prax*, 1998, **77**, 1219-1223.
- 24 Richard V, Auwera P V D, Snoeck R, Daneau D and Meunier F, Nosocomial bacteremia caused by *Bacillus* species, *Eur J Clin Microbiol Infect Dis*, 1988, **7**, 783-785.
- 25 Curran J P and Al-Salihi F L, Neonatal staphylococcal scalded skin syndrome: Massive outbreak due to an unusual phage type, *Pediatrics*, 1980, **66**(2), 285-90.
- 26 Julander I, Unfavourable prognostic factors in *Staphylococcus aureus* septicemia and endocarditis, *Scand J Infect Dis*, 1985, **17**, 179-87.
- 27 Cluff L E, Reynolds R C, Page D L and Breckenridge J L, Staphylococcal bacteremia and altered host resistance, *Ann Intern Med*, 1968, **69**, 859-73.
- 28 Orrett F A and Land M, Methicillin-resistant *Staphylococcus aureus* prevalence: Current susceptibility patterns in Trinidad, *BMC Infect Dis*, 2006, **6**, 1-83
- 29 Subramanian S S and Nagarjan S, Flavonoids of the seeds of *Crotalaria retusa* and *Crotalaria striata*, *Curr Sci*, 1969, **38**, 65.
- 30 Ramawat K G and Merillon J M, Biotechnology: Secondary Metabolites, Science Pub Inc, 2000.
- 31 Tomita Y, Uomori A and Minato H, Steroidal sapogenins and sterols in tissue cultures of *Dioscorea tokora*, *Phytochemistry*, 1970, **9**, 111-114.
- 32 Andrews J M, BSAC standardized disc susceptibility testing method, *J Antimicrob Chemother*, 2001, **4**, 43-57.
- 33 Basri D F and Fan S H, The potential of aqueous and acetone extracts of gall of *Quercus infectoria* as antibacterial agents, *Indian J Pharmacol*, 2005, **37**, 26-29.
- 34 Eloff J N, Quantifying the bioactivity of the plant extracts during screening and bioassay-guided fractionation, *Phytomedicine*, 2004, **11**(4), 370-371.
- 35 Mahesh B and Satish S, Antimicrobial activity of some important medicinal plants against plant and human pathogens, *World J Agric Sci*, 2008, **4**, 839-843.
- 36 Iwu M W, Duncan A R and Okunji C O, New antimicrobials of plant origin In: Perspectives on new crops and new uses, J Janick, ed, ASHS Press, Alexandria, VA, 1999, 457-462.
- 37 Padamanabhan V, Ganapathy M and Evanjelene V K, Preliminary phytochemical and anti-bacterial studies on flowers and pods of *Albizia lebeck* (Benth), *Int J Emerg Tech Adv Engineer*, 2013, **3**(9), 541-544.
- 38 Chaddha V, Nayak S and Solanki S, Preliminary phytochemical screening on bark & pods of *Albizia lebeck* L. *Pharmacie Globale*, 2011, **11** (6), 1-3.
- 39 Anthonamma K, Prasad S H K R, Rajasekhar D, Swapna N Land Prasad M, *In vitro* antimicrobial efficacy of solvent extracts of seeds of *Albizia lebeck* (L.) Benth, *Int J Adv Pharm Sci*, 2010, **1**, 281-283.
- 40 Srinivasa D, Sangeetha N, Suresh T and Lakshmanan P, Antimicrobial activity of certain Indian medicinal plants use in folkloric medicine, *J Ethnopharmacol*, 2001, **74**, 217-220.